🇺🇸 미국주식 도서
박종훈의 미국주식투자 레시피 : 경제뉴스 꿀조합과 투자…
18,000원
최소한의 주식투자:ETF부터 코스피·미국 주식까지 평생…
19,800원
박종훈의 미국주식투자 레시피:월가의 정보를 수익으로 바…로켓
18,000원
이 포스팅은 쿠팡 파트너스 활동의 일환으로, 이에 따른 일정액의 수수료를 제공받습니다.
| 항목 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $41.00M | $4.46B | $8.03B | $2.97B | $2.91B | $3.54B | $7.77B | $2.69B |
| EPS (Diluted) | $0.01 | $0.78 | $1.41 | $0.52 | $0.51 | $0.62 | $1.36 | $0.47 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Geno...
🔗 emfls.com 다른 콘텐츠 보기